Login to Your Account

In The Clinic NEWS

Dipexium Pharmaceuticals Inc. is still sorting through data from a pair of identical phase III trials, but top-line findings in mild infections of diabetic foot ulcers with the company's lead – and only – product did nothing to encourage investors, and shares tumbled 78 percent.

Aduro Biotech Inc. CEO Stephen Isaacs said the company suspects "more of a port issue" than anything else with the latest problem in pancreatic cancer trials with products based on the Listeria-based immunotherapy construct platform.

Cerecor Inc.'s CMO, Ronald Marcus, acknowledging that upbeat phase III data from Alkermes plc in major depressive disorder MDD whetted appetites for his firm's pair of earlier-stage candidates, said tweaks in trial design can "dramatically improve your probability of success."

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: